Plavix

Lung Neoplasms

Yonsei UniversityN/AActive

D

30/ 100

Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence: 15/ 100
Competitive Position: 73/ 100

Competitive context

47 Active assets in the Lung Neoplasms cohort.

Asset / Sponsor	Phase	Rating
Carboplatin Nanfang Hospital, Southern Medical University	Phase 4	BB
Icotinib Fuda Cancer Hospital, Guangzhou	Phase 4	BB
Cyclophosphamide Pfizer	Phase 3	BB
CIS-DIAMMINEDICHLOROPLATINUM II Nanfang Hospital, Southern Medical University	Phase 3	B
Docetaxel Merck Sharp & Dohme LLC	Phase 3	B

View all 50 →

Same molecule, other indications

Plavix is also rated in:

myocardial infarctionDormant

A

Indicative ·

81 / 100

transient ischemic attackDormant

BBB

Indicative ·

77 / 100

peripheral arterial diseaseDormant

BBB

Indicative ·

77 / 100

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.